To hear about similar clinical trials, please enter your email below

Trial Title: DNA Analysis of Blood and Tissue From Patients With Lung Cancer

NCT ID: NCT00471978

Condition: Lung Cancer

Conditions: Official terms:
Lung Neoplasms

Conditions: Keywords:
non-small cell lung cancer
small cell lung cancer
pulmonary carcinoid tumor

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Retrospective

Summary: RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.

Detailed description: OBJECTIVES: - Assess the role of genetic polymorphisms in lung-cancer risk in patients with lung cancer. - Assess the role of germline polymorphisms in DNA repair genes, p53 pathway genes, and a matrix metalloproteinase gene (tumor invasion factor) in lung-cancer risk, after adjusting for potential confounders. - Assess the roles of gender and age in the genetic susceptibility of lung cancer. - Assess the role of genetic polymorphisms in modifying the diet-lung cancer risk association (gene-diet and exploratory gene-gender-diet and gene-gene-diet interactions). - Assess the role of polymorphisms on the risk of developing specific histologic subtypes of lung cancer in case-only analyses. - Determine whether continued exposures to mainstream and/or second-hand tobacco smoking is associated with poorer clinical prognosis in patients treated for lung cancer. OUTLINE: This began as a case-control study, but is currently case only. Blood samples are collected from patients and controls. Samples are analyzed by polymerase chain reaction for gene polymorphisms. Genes to be studied include GSTP1, GSTM1, GSTT1, ERCC2, XRCC1, EPHX, NAT-2, p53 gene, CYP1A1, NQO1, MnSOD, and GPX1. Tissue samples collected from patients undergoing surgery and blood samples are archived for future studies. Patients and controls complete questionnaires about diet, medical history, and occupational/environmental history. PROJECTED ACCRUAL: A total of 3,400 patients and 3,400 controls will be accrued for this study.

Criteria for eligibility:

Study pop:
Patients with lung cancer

Sampling method: Non-Probability Sample
Criteria:
DISEASE CHARACTERISTICS: - Patient: - Newly diagnosed primary lung cancer - Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified EXCLUSIONS: Vulnerable populations are excluded. Patients with metastasis from another site to lung or mesothelioma are excluded.

Gender: All

Minimum age: 18 Years

Maximum age: 120 Years

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Massachusetts General Hospital

Address:
City: Boston
Zip: 02114
Country: United States

Status: Recruiting

Contact:
Last name: Clinical Trials Office - Massachusetts General Hospital

Phone: 877-726-5130

Facility:
Name: Harvard School of Public Health

Address:
City: Boston
Zip: 02115
Country: United States

Status: Recruiting

Contact:
Last name: David C. Christiani, MD

Phone: 617-726-9274

Start date: September 2005

Completion date: September 2023

Lead sponsor:
Agency: Massachusetts General Hospital
Agency class: Other

Collaborator:
Agency: National Cancer Institute (NCI)
Agency class: NIH

Source: Massachusetts General Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT00471978

Login to your account

Did you forget your password?